MAX and MYC: A heritable breakup

Cancer Research

Volumn 72, Issue 13, 2012, Pages 3119-3124

  Cascoń, Alberto ^a,b   Robledo, Mercedes ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAX DIMERIZATION PROTEIN 1; MYC ASSOCIATED PROTEIN X; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; REGULATOR PROTEIN; SUNITINIB; UNCLASSIFIED DRUG;

AUTOSOMAL INHERITANCE; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DIMERIZATION; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; LOSS OF FUNCTION MUTATION; MAX GENE; MEDULLOBLASTOMA; METASTASIS POTENTIAL; MXI1 GENE; NEUROBLASTOMA; ONCOGENE MYC; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; GENES, MYC; GERM-LINE MUTATION; HUMANS; NEOPLASMS;

EID: 84863605700     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3891     Document Type: Review

References (43)

1. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-99. (Pubitemid 32037520)
2. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011;43:663-7.
3. Cascón A, Pita G, Burnichon N, Landa I, López- Jiménez E, Montero-Conde C, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab 2009;94:1701-5.
4. López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010;24:2382-91.
5. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003;112:193-205. (Pubitemid 36144109)
6. Ribon V, Leff T, Saltiel AR. c-Myc does not require max for transcriptional activity in PC-12 cells. Mol Cell Neurosci 1994;5:277-82. (Pubitemid 24172510)
7. Gallant P, Steiger D. Myc's secret life without Max. Cell Cycle 2009;8:3848-53.
8. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-67. (Pubitemid 14202914)
9. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6. (Pubitemid 16216827)
10. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006;66:2826-33.
11. Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol 2001;36:28-31. (Pubitemid 32052991)
12. Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, et al. Comparison of primary neuroblastoma tumors and derivative earlypassage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res 2009;69:4143-9.
13. Gattolliat CH, Thomas L, Ciafrè SA, Meurice G, Le Teuff G, Job B, et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer 2011;105:1352-61.
14. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45. (Pubitemid 41081267)
15. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983;35:603-10. (Pubitemid 14168364)
16. Bertino JR. Encyclopedia of cancer. 2nd ed. San Diego/London: Academic; 2002.
17. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
18. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002;99:3830-5.
19. van Bokhoven H, Celli J, van Reeuwijk J, Rinne T, Glaudemans B, van Beusekom E, et al. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat Genet 2005;37:465-7.
20. O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, Schwab R, et al. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet 2000;24: 113-9. (Pubitemid 30094709)
21. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Mycresponsive genes in G0 cells. Science 2002;296:1132-6. (Pubitemid 34517133)
22. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997;57:4905-12. (Pubitemid 27469001)
23. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997;57:4905-12. (Pubitemid 27469001)
24. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998;393:483-7. (Pubitemid 28292197)
25. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MXI1 gene in prostate cancer. Nat Genet 1995;9:249-55.
26. Hurlin PJ, Huang J. The MAX-interacting transcription factor network. Semin Cancer Biol 2006;16:265-74. (Pubitemid 44311036)
27. Dezfouli S, Bakke A, Huang J, Wynshaw-Boris A, Hurlin PJ. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol 2006;26:2080-92. (Pubitemid 43346912)
28. Sommer A, Waha A, Tonn J, S̈orensen N, Hurlin PJ, Eisenman RN, et al. Analysis of the Max-binding protein MNTin human medulloblastomas. Int J Cancer 1999;82:810-6. (Pubitemid 29384330)
29. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4. (Pubitemid 34743102)
30. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7. (Pubitemid 39472236)
31. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, et al. Sustained regression of tumors upon MYCinactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 2006;103:16266-71. (Pubitemid 44715185)
32. Huang Z, Traugh JA, Bishop JM. Negative control of the Myc protein by the stress-responsive kinase Pak2. Mol Cell Biol 2004;24:1582-94. (Pubitemid 38167080)
33. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
34. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
35. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-83.
36. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5. (Pubitemid 46232887)
37. Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X, et al. Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol 2009;217:597-604.
38. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-76. (Pubitemid 30083066)
39. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005;102:8573-8. (Pubitemid 40862777)
40. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010;42:229-33.
41. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008;105:6584-9. (Pubitemid 351754550)
42. Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003;104:233-7. (Pubitemid 36249800)
43. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001;98:10320-5. (Pubitemid 32803018)